Chromadex (NASDAQ: CDXC) is one of 157 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare Chromadex to similar companies based on the strength of its profitability, valuation, institutional ownership, analyst recommendations, risk, dividends and earnings.

Earnings and Valuation

This table compares Chromadex and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Chromadex $26.81 million -$2.92 million -42.00
Chromadex Competitors $223.44 million -$40.84 million -41.26

Chromadex’s rivals have higher revenue, but lower earnings than Chromadex. Chromadex is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

6.1% of Chromadex shares are owned by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 11.6% of Chromadex shares are owned by insiders. Comparatively, 13.5% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


This table compares Chromadex and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chromadex -21.89% -47.30% -32.25%
Chromadex Competitors -4,652.25% -636.26% -44.32%

Analyst Recommendations

This is a summary of current ratings and target prices for Chromadex and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chromadex 0 0 3 0 3.00
Chromadex Competitors 506 2214 5858 127 2.64

Chromadex presently has a consensus target price of $7.00, indicating a potential upside of 19.05%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 11.11%. Given Chromadex’s stronger consensus rating and higher probable upside, equities analysts plainly believe Chromadex is more favorable than its rivals.

Risk & Volatility

Chromadex has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Chromadex’s rivals have a beta of 1.67, indicating that their average share price is 67% more volatile than the S&P 500.


Chromadex beats its rivals on 7 of the 12 factors compared.

Chromadex Company Profile

Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with's FREE daily email newsletter.